New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview
The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR of 15.8%.
The global antibody-drug conjugates market is expanding due to an increase in the prevalence of cancer and increased utilization of new technologies in ADCs. Whereas, ADCs employ monoclonal antibodies, the distinguished chemical carries cytotoxic chemicals to the cancerous cells, thus reducing toxicity to the other parts of the body.
Current advances in ADC technology have seen market leaders enhance the efficiency of the methods for improved results and reduced side effects. There is growth due to sustaining the development of new ADC candidates and raised R&D requirement on the back of new ADC entrants.
North America takes the largest slice of the market, due to newly developed treatments as well as a great number of pharmaceutical companies.
Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/antibody-drug-conjugates-market/request-sample/
The US Antibody Drug Conjugates (ADCs) Market
The US Antibody Drug Conjugates (ADCs) market is projected to grow from USD 4.9 billion in 2024 to USD 17.1 billion by 2033, at a CAGR of 14.8%.
This market is expanding rapidly because of massive cancer prevalence and well-developed healthcare systems. These are such things as considerable expenditures for research and development, high clinical trial activity, and refractory permissive regulations.
Higher incidence rates of diseases including breast cancer, lymphoma, and leukaemia as well as a rising collaboration between biotech companies and academic institutions also contribute to market growth.
Important Insights
- Market Value: The global antibody-drug conjugates (ADC) market is estimated to be valued at USD 13.7 billion in 2024 and is expected to reach USD 51.2 billion by 2033.
- US Market Size: The US ADC market is projected to be worth USD 4.9 billion in 2024, with expected growth reaching USD 17.1 billion by 2033, at a CAGR of 14.8%.
- Product Segment Analysis: KADCYLA is expected to lead this segment, holding 24.1% of the market share in 2024.
- Target Type Segment Analysis: HER2 is projected to dominate the global ADC market in the target type segment, with a 32.2% market share in 2024.
- Payload Type Segment Analysis: MMAE (Monomethyl Auristatin E) is anticipated to hold the highest market share in this segment in 2024.
- Application Segment Analysis: Blood cancer will dominate the application segment, holding the highest market share in 2024.
- End User Segment Analysis: Hospitals and specialty cancer centers are expected to lead the end-user segment, holding the highest market share in 2024.
- Regional Analysis: North America is expected to have the largest share of the global ADC market, at about 42.7% in 2024.
- Global Growth Rate: The market is growing at a CAGR of 15.8% over the forecast period.
Latest Trends
- Rising Adoption of ADCs in Oncology: The application of ADCs in oncological practice is increasing, since ADC work based on the monoclonal antibodies binding to tumour cells, including cytotoxic drugs. Branded ADCs for instance KADCYLA, ENHERTU, and ADCETRIS promise positive clinical outcomes and more ADCs continue to gain approval.
- Expansion Beyond Oncology: Despite the impressive overall achievements, the primary field of action for ADCs is still oncology, however, current research in this area is aimed at the development of ADCs for non-oncological applications, including autoimmune diseases and infections. This expanding of the therapeutic possibilities mean that there are more chances for a successful development of a market.
Antibody Drug Conjugate Market: Competitive Landscape
The ADC market is very well penetrated, and the key companies are Pfizer, Roche, AstraZeneca, and Seattle Genetics due to innovation, clinical efforts, and partnership approaches. Technological evolutions such as those the one between Daiichi Sankyo and Scripps Research Institute are fostered by partnerships.
Other biotech companies are also progressing with Relatively narrow focuses and innovative targets like ImmunoGen and ADC Therapeutics. Promising development in the manufacturing of ADCs and acquisition of other players are additionally encouraging innovation and new product developments, subsequently increasing acceptance of ADCs in the treatment of cancer globally.
Some of the prominent market players:
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- AstraZeneca
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- Seagen, Inc.
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline plc
- Adc Therapeutics Saa
- ImmunoGen Inc.
- Bayer AG
- Novartis AG
- Agensys Inc.
- Concortis Biotherapeutics
- Other Key Players
Transform your business approach with strategic insights from our report. Get in touch to request our brochure today! : https://dimensionmarketresearch.com/report/antibody-drug-conjugates-market/download-reports-excerpt/
Antibody Drug Conjugate Market Scope
| Report Highlights | Details |
| Market Size (2024) | USD 13.7 Bn |
| Forecast Value (2033) | USD 51.2 Bn |
| CAGR (2024-2033) | 15.8% |
| North America Revenue Share (2024) | 42.7% |
| The US Market Size (2024) | USD 4.9 Bn |
| Historical Data | 2018 - 2023 |
| Forecast Data | 2024 - 2033 |
| Base Year | 2023 |
| Estimate Year | 2024 |
| Segments Covered | By Product, By Target Type, By Technology, By Payload Type, By Application, By End-User |
| Regional Coverage | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Growth Drivers
- Technological Advancements: New linkers and potent payloads, as well as improvements in the conjugation strategies, have resulted in safety and efficacy improvements that fuel the ADC market’s growth.
- Increasing Cancer Prevalence: The growth in cancer incidence positively affects the ADC market, as these drugs target cytotoxic agents directly at cancer cells, enhancing patients’ quality of life and responding to the demand for personalized medicine.
Restraints
- High Development Costs: It is due to the complexity of their creation that ADCs present high development and manufacturing costs, which are poorly designed for the final consumer and bear great financial risks to the pharma companies.
- Regulatory Challenges: Adverse regulatory requirements that target approval of ADCs require serious clinical tests before being accessed in the market and can also be very expensive which may limit market growth.
Growth Opportunities
- Emerging Markets: The Asia-Pacific region, Latin American and the Middle East are opportunities to tap owing to the enhancement of medical facilities and augmented cancer consciousness. Market expansion is also boosted by such factors as favorable regulations.
- Combination Therapies: Cohort utilization of ADCs with other therapy modalities such as immunotherapy or Check Point inhibitors augments therapeutic efficacy, raising the response rates and extent of ADC usage.
Market Analysis
KADCYLA is projected to dominate the global ADC market, holding 24.1% of the market share in 2024. This ADC has been tested for the treatment of HER2-positive breast cancer by conjugating the drug with TRASTUZUMAB together with the cytotoxic agent DM1 and it was observed that the size of the tumor reduced and progression free survival increased.
Market eclipses for several indications and definite clinical trial support has contributed towards establishing a rigid market. Further marketing and distribution strongly help Roche to guarantee KADCYLA’s market leadership in the ADC segment.
Purchase the Competition Analysis Dashboard Today: https://dimensionmarketresearch.com/checkout/antibody-drug-conjugates-market/
Antibody Drug Conjugate Market Segmentation
By Product
- KADCYLA
- ENHERTU
- ADCETRIS
- PADCEV
- TRODELVY
- POLIVY
- Other Products
By Target Type
- HER2 Antibodies
- CD22 Antibodies
- CD30 Antibodies
- CD33 Antibodies
- CD79b Antibodies
- Other Target Types
By Technology
- Type
- Cleavable Linker Antibodies
- Non-cleavable Linker Antibodies
- Linkerless Antibodies
- Linker Technology Type
- VC (Valine-Citrulline)
- Sulfo-SPDB (N-Succinimidyl 4-[2-pyridyldithio]-2-sulfobutanoate)
- VA (Valine-Alanine)
- Hydrazone Linkers
- Disulfide Linkers
- Peptide Linkers
- Others
- Payload Technology
- MMAE (Monomethyl Auristatin E)
- MMAF (Monomethyl Auristatin F)
- DM4 (Maytansine Derivative)
- Camptothecin Derivatives
- PBD (Pyrrolobenzodiazepine) Dimers
- SN-38 (Topoisomerase I Inhibitor)
- Others
By Payload Type
- MMAE/Auristatin
- Calicheamicin
- Maytansinoids
- PBD Dimers
- Camptothecin Derivatives
- SN-38
- Other Payload Type
By Application
- Blood Cancer
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Lung Cancer
- Ovarian Cancer
- Gastric Cancer
- Other Cancers
By End-User
- Hospitals and Specialty Cancer Centers
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Other End Users
Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/antibody-drug-conjugates-market/request-sample/
Regional Analysis
North America is projected to dominate the global ADC market with a 42.7% share in 2024, driven by high cancer incidence and advanced healthcare systems. The pharma industry in this region is strong and the efficient working of the regulatory bodies, including the FDA, and the speedy processes related to clinical trials enhance the market domination.
Further, strong university-industry interface, ongoing improvement in ADC technology, the North American region’s promising novel cancer therapies, and the increasing popularity of ADC therapies collectively strengthen the region’s stance and provide it a firm hold over the ADC market.
By Region
North America
- The U.S.
- Canada
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Discover additional reports tailored to your industry needs
- Urgent Care Apps Market size is expected to hold a market value of USD 3.3 billion in 2024 and is projected to show subsequent growth with a market value of USD 80.3 billion by the end of 2033 at a CAGR of 42.5%.
- Automated Data Processing Market size is expected to reach a value of USD 1,925.1 million in 2024, and it is further anticipated to reach a market value of USD 9,711.4 million by 2033 at a CAGR of 19.7%.
- Cholesterol Testing Market size is expected to reach a value of USD 109.8 billion in 2024, and it is further anticipated to reach a market value of USD 247.5 billion by 2033 at a CAGR of 9.4%.
- Acute Kidney Injury Treatment Market is projected to reach USD 1,944.4 million by the end of 2024 and grow exponentially until an anticipated value of USD 3,818.9 million in 2033 at a CAGR of 7.8%.
- Blood Sensor Market size is expected to reach a value of USD 12.6 billion in 2024, and it is further anticipated to reach a market value of USD 28.4 billion by 2033 at a CAGR of 9.4%.
- Veterinary Monitoring Equipment Market size is expected to reach a value of USD 2,533.6 million in 2024, and it is further anticipated to reach a market value of USD 5,907.5 million by 2033 at a CAGR of 9.9%.
- Ultrasonic Scalpels Market size is expected to reach a value of USD 2,397.6 million in 2024, and it is further anticipated to reach a market value of USD 5,089.1 million by 2033 at a CAGR of 8.7%.
- Revenue Cycle Management Market size is expected to reach a value of USD 326.4 billion in 2024, and it is further anticipated to reach a market value of USD 936.3 billion by 2033 at a CAGR of 13.1%.
- Respiratory Disease Vaccine Market size is expected to reach a value of USD 102.3 billion in 2024, and it is further anticipated to reach a market value of USD 125.3 billion by 2033 at a CAGR of 2.3%.
- Pediatric Medical Device Market size is expected to reach a value of USD 34.9 billion in 2024, and it is further anticipated to reach a market value of USD 70.3 billion by 2033 at a CAGR of 8.1%.
Recent Developments in the Antibody Drug Conjugate Market
2024
- July: Pfizer received FDA approval for a new ADC targeting a specific biomarker in triple-negative breast cancer, providing a novel treatment option for this challenging cancer subtype.
- June: Roche announced promising Phase III trial results for their ADC targeting HER2-positive gastric cancer, demonstrating improved overall survival compared to standard chemotherapy.
2023
- December: Seattle Genetics obtained EMA approval for their ADC targeting relapsed and refractory multiple myeloma, marking its debut in the European market.
- November: AstraZeneca expanded its ADC manufacturing capabilities with a new state-of-the-art facility to meet the increasing global demand.
- October: Daiichi Sankyo formed a strategic partnership with Scripps Research Institute to develop next-generation ADCs featuring innovative payloads and linker technologies.
- September: GlaxoSmithKline initiated a Phase I clinical trial for a new ADC targeting a unique antigen in small-cell lung cancer, reflecting the growing pipeline of ADCs across various cancer types.
- August: Merck & Co. presented data at the American Society of Clinical Oncology (ASCO) showing their ADC's potential when combined with an immune checkpoint inhibitor, resulting in enhanced anti-tumor activity.
- July: Bristol-Myers Squibb launched a Phase II trial for their ADC aimed at treating metastatic colorectal cancer, addressing a significant unmet need in this patient group.
- June: Novartis announced that their leading ADC candidate received orphan drug designation for a rare sarcoma, potentially accelerating its development and approval.
- May: AbbVie secured breakthrough therapy designation from the FDA for their ADC targeting CD123 in acute myeloid leukemia, highlighting its potential to transform treatment for this aggressive cancer.
About Dimension Market Research (DMR)
Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.
We also believe that our clients don’t always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.
